Nasus Pharma enrolls first patient in Phase 1 trial of intranasal ondansetron candidate NS003

Nasus Pharma enrolled and dosed the first patient in a Phase 1 trial of NS003, an intranasal ondansetron formulation, with first-in-human pharmacokinetic and safety readouts expected before year-end.